Phase 1 Study to Evaluate Safety, and Preliminary Efficacy of Pasireotide LAR in Castration Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2017
At a glance
- Drugs Pasireotide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 07 Jun 2017 Biomarkers information updated
- 06 May 2017 Planned End Date changed from 1 Jun 2017 to 30 Sep 2018.
- 06 May 2017 Planned primary completion date changed from 1 Jun 2017 to 30 Sep 2018.